Immuneering Corporation (IMRX) Shares AACR Data Supporting Atebimetinib in Pancreatic Cancer

Immuneering reported AACR data indicating atebimetinib + mGnP was linked to body mass preservation and tumor volume reduction in first-line pancreatic cancer, echoing prior Phase 2a findings and supporting its ongoing Phase 3 MAPKeeper 301 trial.Material DetailsContext by AI AnalystThis is mid-cycl…